@entity364 have increased substantially in @entity1 with @entity3052 as well as in @entity1 receiving allogeneic stem cell transplantations. Most frequently Aspergillus ssp. and Candida ssp. are observed. Despite the recent introduction of new @entity8201 and lipid-based formulations of @entity2379 , there are few randomized, controlled studies on the use of antifungal drugs in @entity1 with proven invasive @entity364 . Conventional @entity2379 is considered gold standard for the treatment of invasive @entity364 , however is limited by nephrotoxicity and infusion related adverse events. Treatment with @entity8201 , e.g. @entity2380 , @entity2059 or @entity5074 is generally well-tolerated. @entity2380 , however, has no activity against Aspergillus ssp. An additional serious problem is an emerging resistance of non-albicans species to @entity2380 . Lipid-formulations of @entity2379 seem to be attractive alternative, but considerably higher medical costs limit broader application of lipid formulations of @entity2379 . The current strategies for the treatment of documented @entity364 as well as the role of new antifungal agents are discussed in this review.

[Therapy of invasive organ mycoses in XXXX with systemic hematologic diseases].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B', 'Amphotericin B'] @entity2380 :: ('MESH:D015725', 'Chemical') :: ['Fluconazole', 'fluconazole'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute leukemia'] @entity364 :: ('MESH:D009181', 'Disease') :: ['Fungal infections', 'fungal infections'] @entity5074 :: ('MESH:C102790', 'Chemical') :: ['voriconazole'] @entity8201 :: ('MESH:D001393', 'Chemical') :: ['azoles'] @entity2059 :: ('MESH:D017964', 'Chemical') :: ['itraconazole']
@entity1 :: (9606,Species) :: ['patients']
